{"doi":"10.1016/j.rpth.2023.101424","title":"PB0292 Thrombotic Risk Evaluation in Pediatric Patients with Acute Lymphoblastic Leukemia Using Thrombin Generation Test","abstract":"Results: In a cohort of 47 pediatric MPN patients, 6 patients were identified to have VTE.All six patients were female.Four patients had a JAK2 mutation, one patient had an MPL mutation, and one patient was negative for known driver mutations.Among VTE types, 4 patients had Budd Chiari syndrome, and 2 patients had cerebral venous sinus thromboses (Table 1).All patients were treated at some point with anticoagulant therapy for management of their VTE events.Anticoagulants used included apixaban, rivaroxaban, warfarin, enoxaparin, and fondaparinux.One patient had a CNS bleeding event while on enoxaparin (and did not have aVWD at the time), while no other patients experienced significant bleeding.Table 1: Summary of thrombotic and bleeding complications. Conclusion(s):In this cohort of pediatric MPN patients, 12.7% of children required anticoagulation for a VTE.Only one of those patients had a significant bleeding event on anticoagulation, and patients on direct oral anticoagulants did not have bleeding.Anticoagulation can be a safe and important part of the treatment of children with MPNs and VTE and more study is needed to evaluate bleeding risk in this population.","journal":"Research and Practice in Thrombosis and Haemostasis","year":2023,"id":413866,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9383,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2023-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1195425,"name":"Anna Ruiz‐Llobet","orcid":"0000-0002-0155-7922","position":1,"is_corresponding":false},{"id":1195426,"name":"Susanna Gassiot","orcid":"0000-0001-5506-0244","position":2,"is_corresponding":false},{"id":1195427,"name":"Edurne Sarrate","orcid":"0000-0003-2860-5557","position":3,"is_corresponding":false},{"id":1195428,"name":"Josune Zubicaray","orcid":"0000-0003-4115-9598","position":4,"is_corresponding":false},{"id":1195429,"name":"Susana Rives","orcid":"0000-0002-5658-1831","position":5,"is_corresponding":false},{"id":1195779,"name":"Warda Suleman","orcid":null,"position":6,"is_corresponding":false},{"id":1195424,"name":"Rubén Berrueco","orcid":"0000-0002-1068-7489","position":0,"is_corresponding":true}],"reference_count":0,"raw_metadata":null,"created_at":"2026-07-19T01:22:01.321790Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}